Table 1:
Clinical characteristics of 31 patients who underwent HSCT and then developed de novo glomerulonephritis.
| Age (years) | 49.0 ± 14.3 |
| Sex (M/F) | 19/12 |
| Underlying haematological disorders, n (%) | |
| ALL | 8 (25.8) |
| AML | 9 (29.0) |
| Lymphoma | 5 (16.1) |
| MDS/SAA | 2 (6.4) |
| Multiple myeloma | 2 (6.4) |
| CML | 2 (6.4) |
| Others | 3 (9.7) |
| Type of HSCT | |
| URD | 12 (38.7) |
| HLA-matched sibling | 10 (32.3) |
| Haploidentical related | 3 (9.6) |
| Autologous | 6 (19.4) |
| Number of HLA mismatches | 0.68 ± 1.25 |
| Conditioning regimen, n (%) | |
| Bu-CYC | 7 (22.6) |
| CYC-TBI | 11 (35.5) |
| Mini-TBI | 2 (6.4) |
| Flu-CYC | 3 (9.7) |
| Big CBV | 2 (6.4) |
| Others | 6 (19.4) |
| Maintenance regimen, n (%) | |
| PRED + CYA ± MMF | 7 (22.6) |
| CYA + MMF | 8 (25.8) |
| PRED alone | 3 (9.7) |
| Others | 13 (41.9) |
| Presence of GVHD, n (%) | 15 (48.4) |
| Time to GN (years) | 2.8 ± 2.7 |
| Renal histology, n (%) | |
| TMA | 12 (38.7) |
| MN | 8 (25.8) |
| MesPGN | 4(12.9) |
| MCN | 3 (9.7) |
| FSGS | 3 (9.7) |
| MPGN | 1 (3.2) |
| Patient demographics and medical comorbidities | |
| Body weight (kg) | 63.1 ± 14.1 |
| Diabetes mellitus, n (%) | 6 (19.4) |
| Hypertension, n (%) | 11 (35.5) |
| Presence of monoclonal gammopathy, n (%) | 1 (3.2) |
| Urinary protein prior to development of renal disease (g/day) | 0.24 ± 0.42 |
| SCr level prior to development of renal disease (µmol/L) | 99 ± 37 |
| Use of anti-hypertensives (including RAAS blockade), n (%) | |
| None | 20 (64.5) |
| One anti-hypertensive | 8 (25.8) |
| Two anti-hypertensives | 3 (9.7) |
| Use of RAAS blockade | 2 (6.5) |
| Renal parameters at presentation | |
| eGFR (mL/min/1.73 m2) | 50.8 ± 25.4 |
| Urinary protein excretion (g/day) | 4.1 ± 5.3 |
| Haemoglobin level (g/dL) | 11.3 ± 2.1 |
| Platelet count (×109/L) | 169.4 ± 94.8 |
Data are presented as mean ± SD or n (%).
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BEAM, carmustine/etoposide/cytarabine/melphalan; Bu, busulphan; CBV, cyclophosphamide/carmustine/etoposide; CML, chronic myeloid leukemia; CYC, cyclophosphamide; MDS, myelodysplastic syndrome; RAAS, renin–angiotensin–aldosterone system; SAA, severe aplastic anemia; SCr, serum creatinine.